FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Hertl

Research Profile

Disorders

Chemicals & Drugs

Anatomy

Procedures

Co-author Network

Publications

TOP 3
Christian Möbs; Arnd Petersen; Michael Hertl; Henrik Ipsen; Lea Mayer; Caroline Slotosch; Peter A Würtzen; Wolfgang Pfützner
Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.
Giovanni Di Zenzo; Biagio Didona; Rudiger Eming; Takashi Hashimoto; Michael Hertl; Masayuki Amagai; Valentina Calabresi; Giuseppe Cianchini; Davide Corti; Giulia Di Lullo; Bungo Ohyama; Federica Sallusto; Anna Sinistro; Jerry Sloostra; Fabrizia Vanzetta; Giovanna Zambruno; Antonio Lanzavecchia
Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface.
Michael Kasperkiewicz; Michael Meurer; Hendrik Schulze-Koops; Peter von Wussow; Detlef Zillikens; Melika Behzad; Thomas Dörner; Rüdiger Eming; Klaus Freivogel; Michael Hertl; Nicolas Hunzelmann; Enno Schmidt
Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Hertl (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Christian Möbs; Arnd Petersen; Michael Hertl; Henrik Ipsen; Lea Mayer; Caroline Slotosch; Peter A Würtzen; Wolfgang Pfützner
Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.
The Journal of allergy and clinical immunology 2012;130(5):1108-1116.e6.
2012: Giovanni Di Zenzo; Biagio Didona; Rudiger Eming; Takashi Hashimoto; Michael Hertl; Masayuki Amagai; Valentina Calabresi; Giuseppe Cianchini; Davide Corti; Giulia Di Lullo; Bungo Ohyama; Federica Sallusto; Anna Sinistro; Jerry Sloostra; Fabrizia Vanzetta; Giovanna Zambruno; Antonio Lanzavecchia
Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface.
The Journal of clinical investigation 2012;122(10):3781-90.
2012: Michael Kasperkiewicz; Michael Meurer; Hendrik Schulze-Koops; Peter von Wussow; Detlef Zillikens; Melika Behzad; Thomas Dörner; Rüdiger Eming; Klaus Freivogel; Michael Hertl; Nicolas Hunzelmann; Enno Schmidt
Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2012;10(10):727-32.
2012: Ofer Sarig; Enno Schmidt; Karl Skorecki; Henri Trau; Detlef Zillikens; Lilach Zoller; Aviv Barzilai; Sharon Baum; Sivan Bercovici; Reuven Bergman; Ariel Darvasi; Dan Geiger; Ilan Goldberg; Michael Hertl; Saleh M Ibrahim; Margarita Indelman; Shirli Israeli; Oren Katz; Helena Martinez de Morentin; Dedee F Murrell; Sagi Nahum; Markus M Nöthen; Shai Rosenberg; Saharon Rosset; Nadav Sagiv; Eli Sprecher
Population-specific association between a polymorphic variant in ST18, encoding a pro-apoptotic molecule, and pemphigus vulgaris.
The Journal of investigative dermatology 2012;132(7):1798-805.
2012: Luca Fania; Claudio Feliciani; Oliver Brandt; G Caldarola; Ralf Müller; Riccardo Pellicano; Michael Hertl
IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses.
Clinical immunology (Orlando, Fla.) 2012;143(3):236-45.
2012: Oliver Brandt; Rüdiger Hein; Michael Hertl; Marcel F Jonkman; Andrea Niedermeier; Hendri H Pas; Eva Podstawa; David Rafei; Jorrit B Terra; Ralf Müller
Differential IgG recognition of desmoglein 3 by paraneoplastic pemphigus and pemphigus vulgaris sera.
The Journal of investigative dermatology 2012;132(6):1738-41.
2012: M Behzad; Michael Hertl; Joachim Hoyer; A Kneisel; C Möbs; M Möller; Rüdiger Eming
Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris.
The British journal of dermatology 2012;166(4):844-52.
2012: Emilia Licarete; Jonas Mudter; Markus F Neurath; Martin J Recknagel; Leena Bruckner-Tuderman; Giovanni Di Zenzo; Susanne Ganz; Takashi Hashimoto; Michael Hertl; Gheorghe Hundorfean; Giovanna Zambruno; Cassian Sitaru
Prevalence of collagen VII-specific autoantibodies in patients with autoimmune and inflammatory diseases.
BMC immunology 2012;13():16.
2012: Benjamin S Daniel; Rüdiger Eming; Michael Hertl; Victoria P Werth; Dédée F Murrell
Severity score indexes for blistering diseases.
Clinics in dermatology 2012;30(1):108-13.
2011: Andrea Kneisel; Michael Hertl
Autoimmune bullous skin diseases. Part 2: diagnosis and therapy.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2011;9(11):927-47.
2011: Giovanni Di Zenzo; Lionel Fontao; Luca Borradori; Leena Bruckner-Tuderman; Valentina Calabresi; Silke C Hofmann; Jean-Philippe Lacour; Francesco Sera; Sybille Thoma-Uszynski; Giovanna Zambruno; Michael Hertl
Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study.
The Journal of investigative dermatology 2011;131(11):2271-80.
2011: Andrea Kneisel; Michael Hertl
Autoimmune bullous skin diseases. Part 1: Clinical manifestations.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2011;9(10):844-56; quiz 857.
2011: Michael Hertl; Philippe Bernard; Luca Borradori
Rituximab for severe mucous membrane pemphigoid: safe enough to be drug of first choice?
Archives of dermatology 2011;147(7):855-6.
2011: David Rafei; Ralf Müller; Norito Ishii; Maria Llamazares; Takashi Hashimoto; Michael Hertl; Rüdiger Eming
IgG autoantibodies against desmocollin 3 in pemphigus sera induce loss of keratinocyte adhesion.
The American journal of pathology 2011;178(2):718-23.
2011: Kinga Csorba; Florina Florea; Takashi Hashimoto; Michael Hertl; Norito Ishii; Sarolta Kárpáti; Wataru Nishie; Sabine Schmidt; Leena Bruckner-Tuderman; Cassian Sitaru
Development of an ELISA for sensitive and specific detection of IgA autoantibodies against BP180 in pemphigoid diseases.
Orphanet journal of rare diseases 2011;6():31.
2010: Susanne László; Susanne Neumann; Michael Hertl; Nicolas Hunzelmann
Generation of increased numbers of HLA-DR(high) IgG+ plasma cells in the peripheral blood of patients with bullous pemphigoid: NC16a-specific cells belong to the short-lived plasma blast population.
The Journal of investigative dermatology 2010;130(12):2838-41.
2010: Nils Nilles; Andrea Kneisel; Armin Bender; Michael Hertl
[Strip-shaped erythema under polychemotherapy].
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2010;8(10):849-50.
2010: Michael Hertl; Andrea Niedermeier; Luca Borradori
[Autoimmune bullous skin disorders].
Therapeutische Umschau. Revue thérapeutique 2010;67(9):465-82.
2010: Spiro Getsios; Jens Waschke; Luca Borradori; Michael Hertl; Eliane J Müller
From cell signaling to novel therapeutic concepts: international pemphigus meeting on advances in pemphigus research and therapy.
The Journal of investigative dermatology 2010;130(7):1764-8.
2010: Barbara Horváth; Andrea Niedermeier; Eva Podstawa; Ralf Müller; Nicolas Hunzelmann; Sarolta Kárpáti; Michael Hertl
IgA autoantibodies in the pemphigoids and linear IgA bullous dermatosis.
Experimental dermatology 2010;19(7):648-53.
2010: Vicky Bekou; Ralf Müller; Daniela Goeppner; Ingolf Franke; Michael Hertl; Harald Gollnick; Martin Leverkus
Pemphigus vulgaris of the pompholyx type.
European journal of dermatology : EJD 2010;20(4):516-7.
2010: S Lebeau; R Müller; Isabelle Masouyé; Michael Hertl; Luca Borradori
Pemphigus herpetiformis: analysis of the autoantibody profile during the disease course with changes in the clinical phenotype.
Clinical and experimental dermatology 2010;35(4):366-72.
2010: C M Slotosch; S Hörster; Michael Hertl; E Schultz
[Neutrophil-rich, anaplastic CD30+ T cell lymphoma in conjunction with lymphomatoid papulosis].
Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete 2010;61(6):511-3.
2010: Franziska Carola Eberle; Angelique Holland; Stefan Hörster; Claus Vogelmeier; Michael Hertl
Lichenoid exanthema mimicking graft-versus-host disease associated with obstructive lung disease in a non-transplanted patient.
European journal of dermatology : EJD 2010;20(3):381-5.
2010: Ralf Müller; Christiane Dahler; Christian Möbs; Elke Wenzel; Rüdiger Eming; Gerald Messer; Andrea Niedermeier; Michael Hertl
T and B cells target identical regions of the non-collagenous domain 1 of type VII collagen in epidermolysis bullosa acquisita.
Clinical immunology (Orlando, Fla.) 2010;135(1):99-107.
2010: Angela Nagel; Angelika Lang; Dorothee Engel; Eva Podstawa; Nicolas Hunzelmann; Ornella De Pita; Luca Borradori; Wolfgang Uter; Michael Hertl
Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3.
Clinical immunology (Orlando, Fla.) 2010;134(3):320-30.
2010: Christian Möbs; Caroline Slotosch; Harald Löffler; Thilo Jakob; Michael Hertl; Wolfgang Pfützner
Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation.
Journal of immunology (Baltimore, Md. : 1950) 2010;184(4):2194-203.
2010: Ralf Müller; Nicolas Hunzelmann; Vera Baur; Guido Siebenhaar; Elke Wenzel; Rüdiger Eming; Andrea Niedermeier; Philippe Musette; Pascal Joly; Michael Hertl
Targeted immunotherapy with rituximab leads to a transient alteration of the IgG autoantibody profile in pemphigus vulgaris.
Dermatology research and practice 2010;2010():321950.
2010: Franziska C Eberle; Kamran Ghoreschi; Michael Hertl
Fumaric acid esters in severe ulcerative necrobiosis lipoidica: a case report and evaluation of current therapies.
Acta dermato-venereologica 2010;90(1):104-6.
2009: Simone Heimann; Michael Hertl; Jan Skrzypek
[Scaling erythemas in an infant].
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2009;7(12):1087-9.
2009: Rolf Mueller; B Heber; T Hashimoto; G Messer; R Müllegger; Andrea Niedermeier; Michael Hertl
Autoantibodies against desmocollins in European patients with pemphigus.
Clinical and experimental dermatology 2009;34(8):898-903.
2009: Alexander Enk; Gerhard Fierlbeck; Lars French; Michael Hertl; Gerald Messer; Michael Meurer; Kerstin Steinbrink; Georg Stingl; Beatrice Volc-Platzer; Detlef Zillikens
Use of high-dose immunoglobulins in dermatology.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2009;7(9):806-812.
2009: Angela Nagel; Eva Podstawa; Markus Eickmann; Hans-Helge Müller; Michael Hertl; Rüdiger Eming
Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris.
The Journal of investigative dermatology 2009;129(9):2202-10.
2009: Claudio Feliciani; G Caldarola; A Kneisel; E Podstawa; Martin Pfütze; W Pfützner; Michael Hertl
IgG autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses.
The British journal of dermatology 2009;161(2):306-12.
2009: Michael Hertl
Research in practice: Treatment of autoimmune bullous disorders.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2009;7(6):500-5.
2009: Cornelia Erfurt; Esther Müller; Sonja Emmerling; Claudia Klotz; Michael Hertl; Gerold Schuler; Erwin S Schultz
Melanoma-associated chondroitin sulphate proteoglycan as a new target antigen for CD4+ T cells in melanoma patients.
International journal of cancer. Journal international du cancer 2009;124(10):2341-6.
2009: Christian Veldman; Andreas Pahl; Michael Hertl
Desmoglein 3-specific T regulatory 1 cells consist of two subpopulations with differential expression of the transcription factor Foxp3.
Immunology 2009;127(1):40-9.
2009: Silke C Hofmann; Ocko Kautz; Michael Hertl; Michael Sticherling; Detlef Zillikens; Leena Bruckner-Tuderman
Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2009;7(3):227-33.
2009: Angela Nagel; Michael Hertl; Rüdiger Eming
B-cell-directed therapy for inflammatory skin diseases.
The Journal of investigative dermatology 2009;129(2):289-301.
2009: Martin Pfütze; Rüdiger Eming; Andrea Kneisel; Uwe Kuhlmann; Joachim Hoyer; Michael Hertl
Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab.
Dermatology (Basel, Switzerland) 2009;218(3):237-45.
2008: Rüdiger Eming; Angela Nagel; Sonja Wolff-Franke; Eva Podstawa; Dirk Debus; Michael Hertl
Rituximab exerts a dual effect in pemphigus vulgaris.
The Journal of investigative dermatology 2008;128(12):2850-8.
2008: A Nagel; Michael Hertl; Rüdiger Eming
[B-cell-depleting antibodies in skin diseases].
Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete 2008;59(10):793-805.
2008: Hana Jedlickova; Jana Racovska; Andrea Niedermeier; Josef Feit; Michael Hertl
Anti-basement membrane zone antibodies in elderly patients with pruritic disorders and diabetes mellitus.
European journal of dermatology : EJD 2008;18(5):534-8.
2008: Giovanni Di Zenzo; Sybille Thoma-Uszynski; Lionel Fontao; Valentina Calabresi; Silke C Hofmann; Thomas Hellmark; Nathalie Sebbag; Cristina Pedicelli; Francesco Sera; Jean-Philippe Lacour; Jörgen Wieslander; Leena Bruckner-Tuderman; Luca Borradori; Giovanna Zambruno; Michael Hertl
Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid.
Clinical immunology (Orlando, Fla.) 2008;128(3):415-26.
2008: Giacomo Caldarola; Andrea Kneisel; Michael Hertl; Claudio Feliciani
Herpes simplex virus infection in pemphigus vulgaris: clinical and immunological considerations.
European journal of dermatology : EJD 2008;18(4):440-3.
2008: Dédée F Murrell; Sarah Dick; A R Ahmed; Masayuki Amagai; Maria A Barnadas; Luca Borradori; Jean-Claude Bystryn; Giuseppe Cianchini; Luis A Diaz; David P Fivenson; Russell Hall; Karen E Harman; Takashi Hashimoto; Michael Hertl; Nico Hunzelmann; Pilar Iranzo; Pascal Joly; Marcel F Jonkman; Yasuo Kitajima; Neil J Korman; Linda K Martin; Daniel Mimouni; Amit G Pandya; Aimee S Payne; David S Rubenstein; Hiroshi Shimizu; Animesh Sinha; David Sirois; Detlef Zillikens; Victoria P Werth
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus.
Journal of the American Academy of Dermatology 2008;58(6):1043-6.
2008: Michael Hertl; Detlef Zillikens; Luca Borradori; Leena Bruckner-Tuderman; Harald Burckhard; Rüdiger Eming; Andreas Engert; Matthias Goebeler; Silke Hofmann; Nicolas Hunzelmann; Franz Karlhofer; Ocko Kautz; Undine Lippert; Andrea Niedermeier; Martin Nitschke; Martin Pfütze; Marcel Reiser; Christian Rose; Enno Schmidt; Iakov Shimanovich; Michael Sticherling; Sonja Wolff-Franke
Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2008;6(5):366-73.
2008: Bernhard Przybilla; Werner Aberer; Andreas J Bircher; Randolph Brehler; Knut Brockow; Heinrich Dickel; Thomas Fuchs; Michael Hertl; Maja Mockenhaupt; Oliver Pfaar; Johannes Ring; Bernhardt Sachs; D Vieluf; Bettina Wedi; Margitta Worm; Torsten Zuberbier; Hans F Merk
Allergological approach to drug hypersensitivity reactions.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2008;6(3):240-3.
2008: Christian Möbs; Caroline Slotosch; Harald Löffler; Wolfgang Pfutzner; Michael Hertl
Cellular and humoral mechanisms of immune tolerance in immediate-type allergy induced by specific immunotherapy.
International archives of allergy and immunology 2008;147(3):171-8.
2008: Arnd Jacobi; Matthias Braeutigam; Vera Mahler; Erwin S Schultz; Michael Hertl
Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study.
Dermatology (Basel, Switzerland) 2008;216(2):133-6.
2008: Ralf Müller; Vera Svoboda; Elke Wenzel; Hans-Helge Müller; Michael Hertl
IgG against extracellular subdomains of desmoglein 3 relates to clinical phenotype of pemphigus vulgaris.
Experimental dermatology 2008;17(1):35-43.
2007: Detlef Zillikens; Kurt Derfler; Rüdiger Eming; Gerhard Fierlbeck; Matthias Goebeler; Michael Hertl; Silke C Hofmann; Franz Karlhofer; Ocko Kautz; Martin Nitschke; Andreas Opitz; Sven Quist; Christian Rose; Stefan Schanz; Enno Schmidt; Iakov Shimanovich; Michael Michael; Fabian Ziller
Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2007;5(10):881-7.
2007: Pascal Joly; Hugo Mouquet; Jean-Claude Roujeau; Michel D'Incan; Danièle Gilbert; Serge Jacquot; Marie-lise GOUGEON; Christophe Bedane; Ralf Muller; Brigitte Dreno; Marie-Sylvie Doutre; Emmanuel Delaporte; Christine Pauwels; Nathalie Franck; Frédéric Caux; Catherine Picard; Emmanuelle Tancrede-Bohin; Philippe Bernard; François Tron; Michael Hertl; Philippe Musette
A single cycle of rituximab for the treatment of severe pemphigus.
The New England journal of medicine 2007;357(6):545-52.
2007: Karl-Heinz Grzeschik; Dorothea Bornholdt; Frank Oeffner; Arne König; María del Carmen Boente; Herbert Enders; Barbara Fritz; Michael Hertl; Ute Grasshoff; Katja Höfling; Vinzenz Oji; Mauro Paradisi; Christian Schuchardt; Zsuzsanna Szalai; Gianluca Tadini; Heiko Traupe; Rudolf Happle
Deficiency of PORCN, a regulator of Wnt signaling, is associated with focal dermal hypoplasia.
Nature genetics 2007;39(7):833-5.
2007: Daniela Bruch-Gerharz; Michael Hertl; Thomas Ruzicka
Mucous membrane pemphigoid: clinical aspects, immunopathological features and therapy.
European journal of dermatology : EJD 2007;17(3):191-200.
2007: Christian Veldman; Rüdiger Eming; Sonja Wolff-Franke; Grete Sonderstrup; William W Kwok; Michael Hertl
Detection of low avidity desmoglein 3-reactive T cells in pemphigus vulgaris using HLA-DR beta 1*0402 tetramers.
Clinical immunology (Orlando, Fla.) 2007;122(3):330-7.
2007: Andrea Niedermeier; Rüdiger Eming; Martin Pfütze; Christine R Neumann; Claudia Happel; Kristian Reich; Michael Hertl
Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies).
Archives of dermatology 2007;143(2):192-8.
2007: Alessandra Marini; Heike Draeger; Matthias Schneider; Andrea Niedermeier; Michael Hertl; Thomas Ruzicka; Ulrich R Hengge
Rowell syndrome with palmoplantar involvement and suspected epitope spreading.
Acta dermato-venereologica 2007;87(3):278-80.
2007: Michael Hertl; Rüdiger Eming; Luca Borradori
Rituximab (anti-CD20 monoclonal antibody)--ultimate or first choice in pemphigus?
Dermatology (Basel, Switzerland) 2007;214(4):275-7.
2007: Martin Pfütze; Andrea Niedermeier; Michael Hertl; Rüdiger Eming
Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus.
European journal of dermatology : EJD 2007;17(1):4-11.
2006: Rüdiger Eming; Michael Hertl
Immunoadsorption in pemphigus.
Autoimmunity 2006;39(7):609-16.
2006: Arnd Jacobi; Vera Mahler; Gerold Schuler; Michael Hertl
Treatment of inflammatory dermatoses by tumour necrosis factor antagonists.
Journal of the European Academy of Dermatology and Venereology : JEADV 2006;20(10):1171-87.
2006: Ralf Müller; Vera Svoboda; Elke Wenzel; Susanne Gebert; Nicolas Hunzelmann; Hans-Helge Müller; Michael Hertl
IgG reactivity against non-conformational NH-terminal epitopes of the desmoglein 3 ectodomain relates to clinical activity and phenotype of pemphigus vulgaris.
Experimental dermatology 2006;15(8):606-14.
2006: Andrea Niedermeier; Petra Wörl; Sandra Barth; Gerold Schuler; Michael Hertl
Delayed response of oral pemphigus vulgaris to rituximab treatment.
European journal of dermatology : EJD 2006;16(3):266-70.
2006: Michael Hertl; Rüdiger Eming; Christian Veldman
T cell control in autoimmune bullous skin disorders.
The Journal of clinical investigation 2006;116(5):1159-66.
2006: Sibylle Eigelshoven; Daniela Bruch-Gerharz; Elaine Enderlein; Thomas Ruzicka; Amanda S Büchau; Michael Hertl; Julia Reifenberger; Klaus W Schulte
[A severe course of bullous pemphigoid in a young man].
Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete 2006;57(4):320-2.
2006: Mario Bittar; Rudolf Happle; Karl-Heinz Grzeschik; Leonora Leveleki; Michael Hertl; Dorothea Bornholdt; Arne König
CHILD syndrome in 3 generations: the importance of mild or minimal skin lesions.
Archives of dermatology 2006;142(3):348-51.
2006: Christian Veldman; Andreas Pahl; Stefan Beissert; Wiebke Hansen; Jan Buer; Detlef Dieckmann; Gerold Schuler; Michael Hertl
Inhibition of the transcription factor Foxp3 converts desmoglein 3-specific type 1 regulatory T cells into Th2-like cells.
Journal of immunology (Baltimore, Md. : 1950) 2006;176(5):3215-22.
2006: Sybille Thoma-Uszynski; Wolfgang Uter; Susanne Schwietzke; Gerold Schuler; Luca Borradori; Michael Hertl
Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230.
Journal of immunology (Baltimore, Md. : 1950) 2006;176(3):2015-23.
2006: Christian Veldman; Angela Nagel; Michael Hertl
Type I regulatory T cells in autoimmunity and inflammatory diseases.
International archives of allergy and immunology 2006;140(2):174-83.
2006: Rüdiger Eming; Jürgen Rech; Sandra Barth; Joachim R Kalden; Gerold Schuler; Thomas Harrer; Michael Hertl
Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption.
Dermatology (Basel, Switzerland) 2006;212(2):177-87.
2006: Rüdiger Eming; Michael Hertl
Autoimmune bullous disorders.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2006;44(2):144-9.
2005: Kerstin L Gebhard; Christian Veldman; Ralf Wassmuth; Erwin S Schultz; Gerold Schuler; Michael Hertl
Ex vivo analysis of desmoglein 1-responsive T-helper (Th) 1 and Th2 cells in patients with pemphigus foliaceus and healthy individuals.
Experimental dermatology 2005;14(8):586-92.
2005: Franziska Mayrshofer; Michael Hertl; Ronald Sinkgraven; Michael Sticherling; Christiane Pfeiffer; Detlef Zillikens; Gerald Messer; Berthold Rzany Für Die Deutschebsd-Studiengruppe
[Significant decrease in quality of life in patients with pemphigus vulgaris. Results from the German Bullous Skin Disease (BSD) Study Group].
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2005;3(6):431-5.
2005: Vicky Bekou; Sybille Thoma-Uszynski; Olaf Wendler; Wolfgang Uter; Susanne Schwietzke; Thomas Hunziker; Christos Zouboulis; Gerold Schuler; Lydia Sorokin; Michael Hertl
Detection of laminin 5-specific auto-antibodies in mucous membrane and bullous pemphigoid sera by ELISA.
The Journal of investigative dermatology 2005;124(4):732-40.
2005: Michael Hertl; Ina Haendle; Gerold Schuler; M Simon
[Annular erythema associated wih pruritus in a 69-year-old female].
Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete 2005;56(4):378-80.
2005: M S Hertl; Ina Haendle; Gerold Schuler; Michael Hertl
Rapid improvement of recalcitrant disseminated granuloma annulare upon treatment with the tumour necrosis factor-alpha inhibitor, infliximab.
The British journal of dermatology 2005;152(3):552-5.
2005: Arnd Jacobi; Christian Antoni; Bernhard Manger; Gerold Schuler; Michael Hertl
Infliximab in the treatment of moderate to severe atopic dermatitis.
Journal of the American Academy of Dermatology 2005;52(3 Pt 1):522-6.
2005: M S Hertl-Yazdi; Michael Hertl
[Bullous drug reactions].
Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete 2005;56(1):16-23.
2004: Sybille Thoma-Uszynski; Wolfgang Uter; Susanne Schwietzke; Silke C Hofmann; Thomas Hunziker; Philippe Bernard; Regina Treudler; Christos Zouboulis; Gerold Schuler; Luca Borradori; Michael Hertl
BP230- and BP180-specific auto-antibodies in bullous pemphigoid.
The Journal of investigative dermatology 2004;122(6):1413-22.
2004: Christian Veldman; Annette Höhne; Detlef Dieckmann; Gerold Schuler; Michael Hertl
Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris.
Journal of immunology (Baltimore, Md. : 1950) 2004;172(10):6468-75.
2004: Christian Veldman; Kerstin L Gebhard; Wolfgang Uter; Ralf Wassmuth; Joachim Grötzinger; Erwin S Schultz; Michael Hertl
T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals.
Journal of immunology (Baltimore, Md. : 1950) 2004;172(6):3883-92.
2003: Silke C Hofmann; K Tamm; Michael Hertl; Luca Borradori
Diagnostic value of an enzyme-linked immunosorbent assay using BP180 recombinant proteins in elderly patients with pruritic skin disorders.
The British journal of dermatology 2003;149(4):910-2.
2003: Matthias Lüftl; Angelika Stauber; A Mainka; R Klingel; Gerold Schuler; Michael Hertl
Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber.
The British journal of dermatology 2003;149(3):598-605.
2003: Michael Hertl; Christian Veldman
T-cellular autoimmunity against desmogleins in pemphigus, an autoantibody-mediated bullous disorder of the skin.
Autoimmunity reviews 2003;2(5):278-83.
2003: Arnd Jacobi; Bernhard Manger; Gerold Schuler; Michael Hertl
[Therapeutic application of TNF-alpha inhibitors infliximab and etanercept in inflammatory skin disorders].
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2003;1(4):259-72.
2003: Alexander Enk; Michael Hertl; Gerald Messer; Michael Meurer; Ellen Rentz; Detlef Zillikens
[The use of high dose intravenous immunoglobulins in dermatology].
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2003;1(3):183-90.
2003: Christian Veldman; Angelika Stauber; Ralf Wassmuth; Wolfgang Uter; Gerold Schuler; Michael Hertl
Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles.
Journal of immunology (Baltimore, Md. : 1950) 2003;170(1):635-42.
2002: Can Baykal; Gülsevim Azizlerli; Sybille Thoma-Uszynski; Michael Hertl
Pemphigus vulgaris localized to the nose and cheeks.
Journal of the American Academy of Dermatology 2002;47(6):875-80.
2002: SilkeC Hofmann; Sybille Thoma-Uszynski; Thomas Hunziker; Philippe Bernard; Corinna Koebnick; Angelika Stauber; Gerold Schuler; Luca Borradori; Michael Hertl
Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain.
The Journal of investigative dermatology 2002;119(5):1065-73.
2002: Berthold Rzany; Karin Partscht; Martin Jung; Werner Kippes; Dieter Mecking; Bozena Baima; Christin Prudlo; Beata Pawelczyk; Elisabeth M Messmer; Monika Schuhmann; Ronald Sinkgraven; Lutz Büchner; Lioba Büdinger; Christiane Pfeiffer; Michael Sticherling; Michael Hertl; Hans-Wilhelm Kaiser; Michael Meurer; Detlef Zillikens; Gerald Messer
Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age.
Archives of dermatology 2002;138(7):903-8.
2002: Christian Maczek; Sybille Thoma-Uszynski; Gerold Schuler; Michael Hertl
[Simultaneous onset of pemphigoid and factor VIII antibody hemophilia].
Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete 2002;53(6):412-5.
2002: Michael Hertl; Gerold Schuler
[Bullous autoimmune dermatoses. 3: Diagnosis and therapy].
Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete 2002;53(5):352-65; quiz 366-7.
2002: Michael Hertl; Gerold Schuler
[Bullous autoimmune dermatoses. 2: Pathogenesis].
Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete 2002;53(4):277-85; quiz 285, 287.
2002: Michael Hertl; Gerold Schuler
[Bullous autoimmune dermatoses. 1: Classification].
Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete 2002;53(3):207-19; quiz 220-1.
2002: T Rädisch; R Riechers; Michael Hertl
The humanized SCID mouse model to study HLA class II-linked autoimmunity to desmoglein 3 in pemphigus vulgaris.
The British journal of dermatology 2002;146(2):189-93.
2001: Constanze Voigtländer; Matthias Lüftl; Gerold Schuler; Michael Hertl
Infliximab (anti-tumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease).
Archives of dermatology 2001;137(12):1571-4.
2001: Lioba Büdinger; N Neuser; U Totzke; Hans F Merk; Michael Hertl
Preferential usage of TCR-Vbeta17 by peripheral and cutaneous T cells in nickel-induced contact dermatitis.
Journal of immunology (Baltimore, Md. : 1950) 2001;167(10):6038-44.
2001: Michael Hertl; Christian Veldman
Pemphigus--paradigm of autoantibody-mediated autoimmunity.
Skin pharmacology and applied skin physiology 2001;14(6):408-18.
2001: Michael Hertl; R Riechers
Autoreactive T cells as potential targets for immunotherapy of autoimmune bullous skin diseases.
Clinics in dermatology 2001;19(5):592-7.
2001: S Spaeth; R Riechers; Luca Borradori; Detlef Zillikens; Lioba Büdinger; Michael Hertl
IgG, IgA and IgE autoantibodies against the ectodomain of desmoglein 3 in active pemphigus vulgaris.
The British journal of dermatology 2001;144(6):1183-8.
2000: Rüdiger Eming; Lioba Büdinger; R Riechers; O Christensen; Heribert Bohlen; R Kalish; Michael Hertl
Frequency analysis of autoreactive T-helper 1 and 2 cells in bullous pemphigoid and pemphigus vulgaris by enzyme-linked immunospot assay.
The British journal of dermatology 2000;143(6):1279-82.
2000: Bernhardt Sachs; Michael Hertl; Hans F Merk
Histamine receptors on lymphocytes: distribution and functional significance.
Skin pharmacology and applied skin physiology 2000;13(6):313-23.
2000: S Christophoridis; Lioba Büdinger; Luca Borradori; T Hunziker; Hans F Merk; Michael Hertl
IgG, IgA and IgE autoantibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis.
The British journal of dermatology 2000;143(2):349-55.
2000: Michael Hertl
Humoral and cellular autoimmunity in autoimmune bullous skin disorders.
International archives of allergy and immunology 2000;122(2):91-100.
2000: Mouna Skaria; Fabienne Jaunin; Thomas Hunziker; Sara Riou; Hauke Schumann; L Bruckner-Tuderman; Michael Hertl; P Bernard; Jean-Hilaire Saurat; Bertrand Favre; Luca Borradori
IgG autoantibodies from bullous pemphigoid patients recognize multiple antigenic reactive sites located predominantly within the B and C subdomains of the COOH-terminus of BP230.
The Journal of investigative dermatology 2000;114(5):998-1004.
2000: Lioba Büdinger; Michael Hertl
Immunologic mechanisms in hypersensitivity reactions to metal ions: an overview.
Allergy 2000;55(2):108-15.
1999: Michael Hertl; R Riechers
Analysis of the T cells that are potentially involved in autoantibody production in pemphigus vulgaris.
The Journal of dermatology 1999;26(11):748-52.
1999: Michael Hertl; Lioba Büdinger; S Christophoridis; Kim B Yancey; Luca Borradori
IgG and IgA antibodies in linear IgA/IgG bullous dermatosis target the ectodomain of bullous pemphigoid antigen 2.
The British journal of dermatology 1999;140(4):750-2.
1999: J Perriard; Fabienne Jaunin; Bertrand Favre; Lioba Büdinger; Michael Hertl; Jean-Hilaire Saurat; Luca Borradori
IgG autoantibodies from bullous pemphigoid (BP) patients bind antigenic sites on both the extracellular and the intracellular domains of the BP antigen 180.
The Journal of investigative dermatology 1999;112(2):141-7.
1999: R Riechers; Joachim Grötzinger; Michael Hertl
HLA class II restriction of autoreactive T cell responses in pemphigus vulgaris: review of the literature and potential applications for the development of a specific immunotherapy.
Autoimmunity 1999;30(3):183-96.
1999: A Arechalde; Ralph P Braun; Anne-Marie Calza; Michael Hertl; Liliane Didierjean; Jean-Hilaire Saurat; Luca Borradori
Childhood bullous pemphigoid associated with IgA antibodies against BP180 or BP230 antigens.
The British journal of dermatology 1999;140(1):112-8.
1998: Lioba Büdinger; Luca Borradori; Carole Yee; Rüdiger Eming; S Ferencik; H Grosse-Wilde; Hans F Merk; Kim B Yancey; Michael Hertl
Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls.
The Journal of clinical investigation 1998;102(12):2082-9.
1998: Hans F Merk; J Baron; Yo Kawakubo; Michael Hertl; Frank K Jugert
Metabolites and allergic drug reactions.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 1998;28 Suppl 4():21-4.
1998: C Haase; Lioba Büdinger; Luca Borradori; Carole Yee; Hans F Merk; Kim B Yancey; Michael Hertl
Detection of IgG autoantibodies in the sera of patients with bullous and gestational pemphigoid: ELISA studies utilizing a baculovirus-encoded form of bullous pemphigoid antigen 2.
The Journal of investigative dermatology 1998;110(3):282-6.
1997: Hans F Merk; J Baron; Michael Hertl; D Niederau; Albert Rübben
Lymphocyte activation in allergic reactions elicited by small-molecular-weight compounds.
International archives of allergy and immunology 1997;113(1-3):173-6.
1996: Hans F Merk; Michael Hertl
Immunologic mechanisms of cutaneous drug reactions.
Seminars in cutaneous medicine and surgery 1996;15(4):228-35.
1995: Michael Hertl; Hans F Merk
Lymphocyte activation in cutaneous drug reactions.
The Journal of investigative dermatology 1995;105(1 Suppl):95S-98S.
1995: Michael Hertl; Frank K Jugert; Hans F Merk
CD8+ dermal T cells from a sulphamethoxazole-induced bullous exanthem proliferate in response to drug-modified liver microsomes.
The British journal of dermatology 1995;132(2):215-20.
1993: Michael Hertl; Heribert Bohlen; Frank K Jugert; C Boecker; R Knaup; Hans F Merk
Predominance of epidermal CD8+ T lymphocytes in bullous cutaneous reactions caused by beta-lactam antibiotics.
The Journal of investigative dermatology 1993;101(6):794-9.
1993: Michael Hertl; J Geisel; C Boecker; Hans F Merk
Selective generation of CD8+ T-cell clones from the peripheral blood of patients with cutaneous reactions to beta-lactam antibiotics.
The British journal of dermatology 1993;128(6):619-26.